Context Therapeutics Inc. (CNTX), a biopharmaceutical firm, announced on Monday the appointment of Andy Pasternak as the new Chairman of its Board of Directors. Pasternak takes over from Richard Berman, who resigned from the Board on January 12.
Prior to this role, Pasternak held the position of Executive Vice President and Chief Strategy Officer at Horizon Therapeutics, a company noted for its focus on treatments for serious and rare autoimmune disorders.
As of now, CNTX shares are trading at $1.05 on the Nasdaq, marking a decline of 2.78 percent or $0.03.
